NCT03660501

Brief Summary

For patients admitted to the medical ward, it is often difficult to predict if their clinical condition will deteriorate, however subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to ICU admission, or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. The WARD-COPD project aims to determine the correlation between cardiopulmonary micro events and clinical adverse events during the first four days after hospital admission with acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2018

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 4, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 6, 2018

Completed
6 days until next milestone

Study Start

First participant enrolled

September 12, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 21, 2020

Completed
Last Updated

August 27, 2020

Status Verified

August 1, 2020

Enrollment Period

1.3 years

First QC Date

September 4, 2018

Last Update Submit

August 26, 2020

Conditions

Keywords

Continuous monitoring

Outcome Measures

Primary Outcomes (1)

  • Any serious adverse events

    E.g. cardiac arrest, ICU admission, acute myocardial infarction, stroke, sepsis, acute kidney injury or other serious adverse events (defined in Protocol Appendix A)

    within 30 days after inclusion

Secondary Outcomes (2)

  • Mortality

    within 6 months after inclusion

  • Readmission

    within 6 months after inclusion

Interventions

Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

200 patients admitted to hospital with acute exacerbation of COPD will be included in the study upon arrival to the medical ward.

You may qualify if:

  • Adult patients admitted with AECOPD
  • Recruitment and monitoring start is possible within 24 hours after admission

You may not qualify if:

  • Patient expected not to cooperate
  • Patient allergic to plaster, plastic or silicone
  • Active therapy withdrawn
  • Patients with dementia or not able to give informed consent
  • Patients with pacemaker or implantable cardioverter-defibrillator (ICD) unit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Bispebjerg Hospital

Copenhagen, 2400, Denmark

Location

Gentofte Hospital

Hellerup, 2900, Denmark

Location

Related Publications (1)

  • Elvekjaer M, Rasmussen SM, Gronbaek KK, Porsbjerg CM, Jensen JU, Haahr-Raunkjaer C, Molgaard J, Sogaard M, Sorensen HBD, Aasvang EK, Meyhoff CS. Clinical impact of vital sign abnormalities in patients admitted with acute exacerbation of chronic obstructive pulmonary disease: an observational study using continuous wireless monitoring. Intern Emerg Med. 2022 Sep;17(6):1689-1698. doi: 10.1007/s11739-022-02988-w. Epub 2022 May 20.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Troponin, Arterial Blood Gas

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Christian Meyhoff, MD, PHD

    Bispebjerg and Frederiksberg Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 4, 2018

First Posted

September 6, 2018

Study Start

September 12, 2018

Primary Completion

December 21, 2019

Study Completion

June 21, 2020

Last Updated

August 27, 2020

Record last verified: 2020-08

Data Sharing

IPD Sharing
Will not share

Locations